Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
July 18 2024 - 12:00PM
Business Wire
Regulatory News:
ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage
biopharmaceutical company developing glenzocimab, an innovative
drug for the treatment of cardiovascular emergencies, today
announces its half-year report on the liquidity contract with the
brokerage firm Kepler Cheuvreux.
Under the liquidity contract entered into between ACTICOR
BIOTECH and Kepler Cheuvreux, the following resources appeared on
the liquidity account on June 30th, 2024:
- 245,176 shares - € 252,168.60 - Number of
executions on buy side on semester: 990 - Number of executions on
sell side on semester: 956 - Traded volume on buy side on semester:
504,480 shares for € 524,812.30 - Traded volume on sell side on
semester: 324,426 shares for € 473,133.44
As a reminder:
- the following resources appeared on the last half year
statement on 31 December 2023 on the liquidity account:
- 65,122 shares - € 299,098.61 - Number of
executions on buy side on semester: 340 - Number of executions on
sell side on semester: 227 - Traded volume on buy side on semester:
39,590 shares for € 173,764.12 - Traded volume on sell side on
semester: 17,891 shares for € 85,132.33
- the following resources appeared on the liquidity account when
the activity started:
- 0 shares - € 600,000.00
The implementation of this report is carried out in accordance
with AMF Decision N°2021-01 of June 22nd 2021 renewing the
implementation of liquidity contracts for shares as an accepted
market practice.
About ACTICOR BIOTECH
Acticor Biotech is a clinical-stage biopharmaceutical company
developing glenzocimab, an innovative drug for the treatment of
cardiovascular emergencies, particularly ischemic stroke.
The positive results of the phase 1b/2a study, ACTIMIS,
published in January 2024 in the Lancet Neurology (link to
publication) confirmed the safety profile of glenzocimab and showed
a reduction in mortality and intracerebral hemorrhage in the
glenzocimab-treated group of stroke patients. A post-hoc analysis
of brain imaging at 0 and 24 hours using artificial intelligence
confirmed these results, showing a reduction in the number and
volume of intracerebral lesions in patients treated with
glenzocimab.
On April 25, 2024, the company announced the initial results of
the international phase 2/3 ACTISAVE study in the treatment of
acute ischemic stroke, which showed no efficacy of glenzocimab on
the primary endpoint, the proportion of patients with severe
disability or death (mRS 4-6) 90 days after stroke, nor on the
secondary endpoint, the proportion of patients returning to life
without disability (mRS 0-2).
On May 15, 2024, Prof. Martin K�hrmann (Principal Investigator
of ACTISAVE) presented the main results of the study at the opening
session of the European Stroke Organization Conference (ESOC),
confirming the neutrality of the study on the primary and secondary
endpoints, and showing trends in return to normal life (mRS 0-1),
notably in sub-populations of patients with complete recanalization
after mechanical thrombectomy.
Glenzocimab is being evaluated in 2 other clinical trials
initiated by academic teams:
- GREEN: a phase 2/3 study in the treatment of stroke in
thrombectomized patients, with a futility analysis after inclusion
of the first 78 patients (30% of patients) expected in Q4
2024;
- LIBERATE: a Phase 2b LIBERATE trial in the treatment of
myocardial infarction, with final results expected in Q4 2025.
Acticor Biotech is supported by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation)
and has been listed on Euronext Growth Paris since November 2021
(ISIN: FR0014005OJ5 - ALACT).
For more information, visit: www.acticor-biotech.com
Buy Side
Sell Side
Number of
executions
Number of
shares
Traded volume in EUR
Number of
executions
Number of
shares
Traded volume in EUR
Total
990
504,480
524,812.30
956
324,426
473,133.44
02/01/2024
1
250
725.00
2
250
737.50
05/01/2024
3
251
740.45
1
1
2.97
08/01/2024
-
-
-
8
750
2,257.50
09/01/2024
-
-
-
5
675
2,112.75
10/01/2024
1
100
306.00
3
25
79.00
11/01/2024
6
901
2,703.00
3
251
778.10
12/01/2024
6
1,223
3,510.01
4
501
1,477.95
15/01/2024
5
500
1,435.00
4
159
457.92
16/01/2024
2
250
710.00
4
108
312.12
17/01/2024
5
500
1,420.00
1
83
237.38
18/01/2024
1
1
2.84
3
501
1,437.87
19/01/2024
3
188
537.68
4
250
725.00
22/01/2024
-
-
-
4
750
2,227.50
23/01/2024
-
-
-
36
6,500
28,535.00
24/01/2024
-
-
-
38
5,726
30,004.24
25/01/2024
17
2,000
8,960.00
8
994
4,622.10
26/01/2024
6
750
3,232.50
3
402
1,776.84
29/01/2024
8
750
3,285.00
7
604
2,742.16
30/01/2024
4
463
2,046.46
3
750
3,367.50
31/01/2024
6
1,037
4,490.21
2
500
2,190.00
01/02/2024
12
1,000
4,260.00
-
-
-
02/02/2024
6
750
3,157.50
2
250
1,090.00
05/02/2024
7
500
2,100.00
5
501
2,134.26
06/02/2024
7
660
2,831.40
4
500
2,200.00
07/02/2024
5
395
1,666.90
3
501
2,169.33
08/02/2024
10
1,274
5,287.10
9
815
3,423.00
09/02/2024
4
267
1,148.10
5
686
3,018.40
12/02/2024
3
503
2,213.20
2
497
2,211.65
13/02/2024
4
731
3,135.99
1
1
4.43
14/02/2024
5
850
3,638.00
3
376
1,650.64
15/02/2024
2
399
1,687.77
-
-
-
16/02/2024
1
250
1,075.00
13
2,123
9,426.12
19/02/2024
3
250
1,100.00
1
250
1,125.00
20/02/2024
6
950
4,284.50
6
1,250
5,700.00
21/02/2024
-
-
-
22
1,877
8,859.44
22/02/2024
-
-
-
14
1,623
8,098.77
23/02/2024
-
-
-
12
1,250
6,287.50
26/02/2024
8
1,250
6,075.00
2
456
2,252.64
27/02/2024
7
751
3,717.45
17
2,244
11,264.88
28/02/2024
3
500
2,510.00
25
2,001
10,145.07
29/02/2024
7
1,001
4,984.98
15
999
5,094.90
01/03/2024
4
1,000
5,020.00
21
3,274
16,992.06
04/03/2024
27
1,748
8,477.80
7
782
3,831.80
05/03/2024
1
5
24.70
15
2,718
13,617.18
06/03/2024
-
-
-
16
1,750
8,925.00
07/03/2024
8
831
4,188.24
3
144
740.16
08/03/2024
27
4,998
22,840.86
9
988
4,544.80
11/03/2024
10
1,940
8,749.40
8
689
3,128.06
12/03/2024
5
651
2,942.52
4
498
2,280.84
13/03/2024
6
950
4,294.00
5
514
2,343.84
14/03/2024
13
2,576
11,257.12
8
702
3,130.92
15/03/2024
28
4,721
15,248.83
-
-
-
18/03/2024
11
2,500
8,250.00
-
-
-
19/03/2024
15
3,100
9,486.00
-
-
-
20/03/2024
11
2,750
7,975.00
-
-
-
21/03/2024
8
1,272
3,739.68
-
-
-
22/03/2024
10
1,978
5,657.08
-
-
-
25/03/2024
7
410
1,271.00
-
-
-
26/03/2024
3
97
300.70
-
-
-
27/03/2024
3
252
806.40
-
-
-
28/03/2024
2
498
1,628.46
-
-
-
02/04/2024
2
500
1,635.00
-
-
-
03/04/2024
2
500
1,610.00
-
-
-
04/04/2024
1
36
118.80
-
-
-
05/04/2024
1
250
835.00
-
-
-
08/04/2024
2
250
850.00
-
-
-
09/04/2024
1
250
850.00
-
-
-
10/04/2024
3
110
374.00
-
-
-
11/04/2024
2
390
1,337.70
-
-
-
12/04/2024
4
500
1,800.00
-
-
-
15/04/2024
3
456
1,673.52
-
-
-
16/04/2024
7
664
2,529.84
2
500
1,965.00
17/04/2024
3
250
975.00
3
699
2,775.03
18/04/2024
1
46
185.84
4
301
1,219.05
19/04/2024
-
-
-
9
1,318
5,496.06
22/04/2024
21
6,943
26,730.55
17
2,250
8,775.00
23/04/2024
3
199
754.21
6
750
2,887.50
24/04/2024
9
2,048
7,864.32
11
2,250
9,022.50
25/04/2024
17
45,000
13,950.00
-
-
-
26/04/2024
53
110,000
42,900.00
-
-
-
29/04/2024
14
6,518
2,542.02
7
5,000
2,100.00
30/04/2024
23
17,982
6,653.34
10
4,000
1,560.00
02/05/2024
21
16,355
6,214.90
7
6,000
2,520.00
03/05/2024
1
1,000
390.00
1
1,000
400.00
06/05/2024
1
1,000
400.00
4
4,000
1,680.00
07/05/2024
5
4,000
2,000.00
48
32,792
17,051.84
08/05/2024
5
4,000
2,840.00
74
44,208
32,713.92
09/05/2024
59
24,740
20,039.40
31
14,412
12,394.32
10/05/2024
16
11,900
7,735.00
34
21,180
16,308.60
13/05/2024
22
11,700
8,892.00
14
8,000
6,320.00
14/05/2024
8
6,000
4,620.00
25
13,000
10,530.00
15/05/2024
-
-
-
47
27,593
28,420.79
16/05/2024
30
16,406
15,913.82
18
11,000
11,550.00
17/05/2024
7
7,000
6,650.00
5
1,227
1,202.46
20/05/2024
19
10,094
9,387.42
9
3,984
3,784.80
21/05/2024
17
9,700
8,827.00
9
4,625
4,301.25
22/05/2024
9
5,000
4,550.00
7
2,274
2,092.08
23/05/2024
6
5,000
4,350.00
1
25
22.75
24/05/2024
11
4,004
3,323.32
-
-
-
27/05/2024
12
5,996
4,916.72
-
-
-
28/05/2024
10
6,000
4,680.00
-
-
-
29/05/2024
10
3,428
2,639.56
4
3,000
2,370.00
30/05/2024
21
13,952
10,045.44
-
-
-
31/05/2024
8
4,620
3,095.40
-
-
-
03/06/2024
-
-
-
10
4,000
3,240.00
04/06/2024
-
-
-
41
24,165
23,681.70
05/06/2024
-
-
-
7
4,915
5,603.10
06/06/2024
11
8,000
7,520.00
2
165
181.50
07/06/2024
2
1,000
920.00
-
-
-
10/06/2024
13
10,000
8,600.00
6
1,000
880.00
11/06/2024
9
4,500
3,780.00
-
-
-
12/06/2024
7
4,001
3,280.82
4
3,001
2,520.84
13/06/2024
18
7,866
6,371.46
1
424
360.40
14/06/2024
27
22,134
15,493.80
31
4,587
3,256.77
17/06/2024
13
9,969
6,778.92
13
5,543
4,046.39
18/06/2024
-
-
-
16
4,300
3,010.00
19/06/2024
7
1,774
1,224.06
-
-
-
20/06/2024
5
1,226
858.20
8
4,800
3,552.00
24/06/2024
2
500
380.00
2
770
592.90
25/06/2024
12
5,000
3,700.00
5
398
302.48
26/06/2024
11
4,019
2,893.68
2
930
669.60
27/06/2024
3
1,001
710.71
1
1
0.72
28/06/2024
7
4,981
3,486.70
-
-
-
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240718435279/en/
ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder
gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD General Manager and CSO
Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Acticor Biotech (EU:ALACT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acticor Biotech (EU:ALACT)
Historical Stock Chart
From Sep 2023 to Sep 2024